The Role of Hypoxia on Prostate Cancer Progression and Metastasis

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2023 Feb 14

PMID 36787054

Authors

Osama A A Mohamed

Heba S Tesen

Marwa Hany

Aya Sherif

Maya Magdy Abdelwahab

Muhammed H Elnaggar

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the second most common cancer diagnosed in men and the fifth-leading cause of cancer death in men worldwide. Like any solid tumor, the hypoxic microenvironment of prostatic cancer drives hypoxia-inducible factors (HIFs) to mediate cell adaptions to hypoxic conditions. HIFs direct different signaling pathways such as PI3K/Akt/mTOR, NOX, and Wnt/β-Catenin to tumor progression depending on the degree of hypoxia. HIFs regulate cytoskeleton protein expression, promoting epithelial-mesenchymal transition (EMT), which occurs when cancer cells lose cell-to-cell adhesions and start invasion and metastasis. Through activating pathways, the hypoxic microenvironment maintains the self-renewal, potency, and anti-apoptotic function of prostate cancer cells and induces tumor metastasis and transformation. These pathways could serve as a potential target for prostate cancer therapy. HIFs increase the expression of androgen receptors on cancer cells maintaining the growth and survival of prostate cancer and the development of its castration resistance. In this review, we elaborate on the role of hypoxia in prostatic cancer pathogenesis and different hypoxia-induced mechanisms.

Citing Articles

Obesity, dietary interventions and microbiome alterations in the development and progression of prostate cancer.

Trecarten S, Liss M, Hamilton-Reeves J, DiGiovanni J Front Immunol. 2025; 15():1448116.

PMID: 39840030 PMC: 11747771. DOI: 10.3389/fimmu.2024.1448116.

Components of the Endosome-Lysosome Vesicular Machinery as Drivers of the Metastatic Cascade in Prostate Cancer.

Nturubika B, Logan J, Johnson I, Moore C, Li K, Tang J Cancers (Basel). 2025; 17(1.

PMID: 39796673 PMC: 11718918. DOI: 10.3390/cancers17010043.

Unveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.

Agostini M, Giacobbi E, Servadei F, Bishof J, Funke L, Sica G Biol Direct. 2024; 19(1):146.

PMID: 39741346 PMC: 11686862. DOI: 10.1186/s13062-024-00492-z.

NOX proteins and ROS generation: role in invadopodia formation and cancer cell invasion.

Quilaqueo-Millaqueo N, Brown-Brown D, Vidal-Vidal J, Niechi I Biol Res. 2024; 57(1):98.

PMID: 39696702 PMC: 11657503. DOI: 10.1186/s40659-024-00577-z.

Adipose Tissues Have Been Overlooked as Players in Prostate Cancer Progression.

Liermann-Wooldrik K, Kosmacek E, Oberley-Deegan R Int J Mol Sci. 2024; 25(22).

PMID: 39596205 PMC: 11594286. DOI: 10.3390/ijms252212137.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

JURASCHEK F, Schoenahl C, Fernandez R, al Salti R, Shikfa M . [Invasive cancer of the prostate. Reconstruction of the lower urinary tract by prostatic resection and ureteral reimplantation into the bladder vault]. Ann Urol (Paris). 1987; 21(1):59-60. View

Mirmoeeni S, Azari Jafari A, Shah M, Salemi F, Hashemi S, Seifi A . The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review. Prostate Cancer. 2022; 2022:5324600. PMC: 9719815. DOI: 10.1155/2022/5324600. View

Muz B, de la Puente P, Azab F, Azab A . The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2016; 3:83-92. PMC: 5045092. DOI: 10.2147/HP.S93413. View

Moreno Roig E, Yaromina A, Houben R, Groot A, Dubois L, Vooijs M . Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis. Front Oncol. 2018; 8:224. PMC: 6004384. DOI: 10.3389/fonc.2018.00224. View

Pouyssegur J, Dayan F, Mazure N . Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006; 441(7092):437-43. DOI: 10.1038/nature04871. View

Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M . The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and Progression. Oxid Med Cell Longev. 2016; 2016:3907147. PMC: 4699039. DOI: 10.1155/2016/3907147. View

Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I . The hypoxic tumour microenvironment. Oncogenesis. 2018; 7(1):10. PMC: 5833859. DOI: 10.1038/s41389-017-0011-9. View

10.

Joyce J . Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005; 7(6):513-20. DOI: 10.1016/j.ccr.2005.05.024. View

11.

Wang G, Jiang B, Rue E, Semenza G . Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92(12):5510-4. PMC: 41725. DOI: 10.1073/pnas.92.12.5510. View

12.

Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

13.

Legler D, Loetscher M, Roos R, Clark-Lewis I, Baggiolini M, Moser B . B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998; 187(4):655-60. PMC: 2212150. DOI: 10.1084/jem.187.4.655. View

14.

Schito L, Rey S, Tafani M, Zhang H, Chak-Lui Wong C, Russo A . Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A. 2012; 109(40):E2707-16. PMC: 3479586. DOI: 10.1073/pnas.1214019109. View

15.

Zhang D, Wang Y, Shi Z, Liu J, Sun P, Hou X . Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation. Cell Rep. 2015; 10(8):1335-48. DOI: 10.1016/j.celrep.2015.02.006. View

16.

Frantz C, Stewart K, Weaver V . The extracellular matrix at a glance. J Cell Sci. 2010; 123(Pt 24):4195-200. PMC: 2995612. DOI: 10.1242/jcs.023820. View

17.

Naba A, Clauser K, Hoersch S, Liu H, Carr S, Hynes R . The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics. 2011; 11(4):M111.014647. PMC: 3322572. DOI: 10.1074/mcp.M111.014647. View

18.

Tuxhorn J, Ayala G, Smith M, Smith V, Dang T, Rowley D . Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002; 8(9):2912-23. View

19.

Gilkes D, Semenza G, Wirtz D . Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014; 14(6):430-9. PMC: 4283800. DOI: 10.1038/nrc3726. View

20.

Erler J, Bennewith K, Cox T, Lang G, Bird D, Koong A . Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2008; 15(1):35-44. PMC: 3050620. DOI: 10.1016/j.ccr.2008.11.012. View